4-amino-7-chloroquinolines: Probing ligand efficiency provides botulinum neurotoxin serotype a light chain inhibitors with significant antiprotozoal activity

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5860-5871

  Opsenica, Igor M ^a   Tot, Mikloš ^a   Gomba, Laura ^b   Nuss, Jonathan E ^b,e   Sciotti, Richard J ^c   Bavari, Sina ^b   Burnett, James C ^d   Šolaja, Bogdan A ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d SAIC FREDERICK INC   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIS AMINOQUINOLINE; BOTULINUM TOXIN A; N (4 BROMOBENZYL) N (4 CHLOROBENZYL)ETHANE 1,2 DIAMINE; N (4 BROMOBENZYL) N (4 CHLOROBENZYL)PROPANE 1,2 DIAMINE; N (7 CHLOROQUINOLIN 4 YL) N (4 FLUOROBENZYL)ETHANE 1,2 DIAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER MICROSOME; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; BOTULINUM TOXINS, TYPE A; HEP G2 CELLS; HUMANS; LIGANDS; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880872690     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4006077     Document Type: Article

References (49)

1. Johnson, E. A.; Bradshaw, M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective Toxicon 2001, 39, 1703-1722
2. Oguma, K.; Fujinaga, Y.; Inoue, K. Structure and function of Clostridium botulinum toxins Microbiol. Immunol. 1995, 39, 161-168
3. Turton, K.; Chaddock, J. A.; Acharya, K. R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility Trends Biochem. Sci. 2002, 27, 552-558
4. Binz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Südhof, T. C.; Jahn, R.; Niemann, H. Proteolysis of SNAP-25 by types E and A botulinum neurotoxins J. Biol. Chem. 1994, 269, 1617-1620
5. Schiavo, G. G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B. R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin Nature 1992, 359, 832-835
6. Schiavo, G.; Malizio, C.; Trimble, W. S.; Polverino de Laureto, P.; Milan, G.; Sugiyama, H.; Johnson, E. A.; Montecucco, C. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond J. Biol. Chem. 1994, 269, 20213-20216
7. Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B. R.; Benfenati, F.; Montecucco, C. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E J. Biol. Chem. 1993, 268, 23784-23787
8. Schiavo, G.; Shone, C. C.; Rossetto, O.; Alexander, F. C.; Montecucco, C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin J. Biol. Chem. 1993, 268, 11516-11519
9. Blasi, J.; Chapman, E. R.; Yamasaki, S.; Binz, T.; Niemann, H.; Jahn, R. Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin EMBO J. 1993, 12, 4821-4828
10. Singh, B. R. Intimate details of the most poisonous poison Nature Struct. Biol. 2000, 7, 617-619
11. Turton, K.; Chaddock, J. A.; Acharya, K. R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility Trends Biochem. Sci. 2002, 27, 552-558
12. Willis, B.; Eubanks, L. M.; Dickerson, T. J.; Janda, K. D. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison Angew. Chem., Int. Ed. Engl. 2008, 47, 8360-8379
13. Emergency Preparedness and Response: Bioterrorism Agents/Diseases; Centers for Disease Control and Prevention: Atlanta, GA; http://emergency.cdc. gov/agent/agentlist-category.asp (accessed 18 Feb 2013).
14. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management JAMA, J. Am. Med. Assoc. 2001, 285, 1059-1070
15. Wein, L. M.; Liu, Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 9984-9989
16. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management JAMA, J. Am. Med. Assoc. 2001, 285, 1059-1070
17. Cai, S.; Singh, B. R. Strategies to design inhibitors of Clostridium botulinum neurotoxins Infect. Disord. Drug Targets 2007, 7, 47-57
18. Burnett, J. C.; Schmidt, J. J.; Stafford, R. G.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Vennerstrom, J. L.; McGrath, C. F.; Lane, D. J.; Sausville, E. A.; Zaharevitz, D. W.; Gussio, R.; Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity Biochem. Biophys. Res. Commun. 2003, 310, 84-93
19. Šolaja, B. A.; Opsenica, D.; Smith, K. S.; Milhous, W. K.; Terzic, N.; Opsenica, I.; Burnett, J. C.; Nuss, J.; Gussio, R.; Bavari, S. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A J. Med. Chem. 2008, 51, 4388-4391
20. Opsenica, I.; Filipovic, V.; Nuss, J. E.; Gomba, l. M.; Opsenica, D.; Burnett, J. C.; Gussio, R.; Šolaja, B. A.; Bavari, S. The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease Eur. J. Med. Chem. 2012, 53, 374-379
21. Malaria Foundation International; Malaria Foundation International: Stone Mountain, GA, 2012; http://www.malaria.org/ (accessed 18 Feb 2013).
22. Wiesner, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. New antimalarial drugs Angew. Chem., Int. Ed. 2003, 42, 5274-5293
23. Wells, T. N.; Alonso, P. L.; Gutteridge, W. E. New medicines to improve control and contribute to the eradication of malaria Nature Rev. Drug Discovery 2009, 8, 879-891
24. Treatment and Prevention of Malaria: Antimalarial Drug Chemistry, Action and Use; Staines, H. M.; Krishna, S., Eds.; Series: Milestones in Drug Therapy; Parnham, M. J.; Bruinvels, J., Series Eds.; Springer: Basel, 2012.
25. V.V. Kouznetsov, V. V.; A. Gómez-Barrio, A. Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation Eur. J. Med. Chem. 2009, 44, 3091-3113
26. Rathore, D.; Jani, D.; Nagarkatti, R.; Kumar, S. Heme detoxification and antimalarial drugs-known mechanisms and future prospects Drug Discovery Today: Ther. Strategies 2006, 3, 153-158
27. Loria, P.; Miller, S.; Foley, S.; Tilley, L. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials Biochem. J. 1999, 339, 363-370
28. Papalexis, V.; Siomos, M. A.; Campanale, N.; Guo, X.; Kocak, G.; Foley, M.; Tilley, L. Histidine-rich protein 2 of the malaria parasite, Plasmodium falciparum, is involved in detoxification of the by-products of haemoglobin degradation Mol. Biochem. Parasitol. 2001, 115, 77-86
29. Ginsburg, H.; Famin, O.; Zhang, J.; Krugliak, M. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action Biochem. Pharmacol. 1998, 56, 1305-1313
30. Foley, M.; Tilley, L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents Pharmacol. Ther. 1998, 79, 55-87
31. Famin, O.; Krugliak, M.; Ginsburg, H. Kinetics of the inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by qantimalarial drugs Biochem. Pharmacol. 1999, 58, 59-68
32. Hastings, I. M.; Bray, P. G.; Ward, S. A. Parasitology. A requiem for chloroquine Science 2002, 298, 74-75
33. Henry, M.; Alibert, S.; Rogier, C.; Barbe, J.; Pradines, B. Inhibition of the efflux of quinolines as a new therapeutic strategy in malaria Curr. Top. Med. Chem. 2008, 8, 563-578
34. Cabrera, M.; Paguio, M. F.; Xie, C.; Roepe, P. D. Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity Biochemistry 2009, 48, 11152-11154
35. Kaur, K.; Jain, M.; Reddy, R. P.; Jain, R. Quinolines and structurally related heterocycles as antimalarials Eur. J. Med. Chem. 2010, 45, 3245-3264
36. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Šolaja, B. A.; Bavari, S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease J. Med. Chem. 2007, 50, 2127-2136
37. Vennerstrom, J. L.; Ager, A. L., Jr.; Dorn, A.; Andersen, S. L.; Gerena, L.; Ridley, R. G.; Milhous, W. K. Bisquinolines. 2. Antimalarial N,N -Bis(7-chloroquinolin-4-yl)heteroalkanediamines J. Med. Chem. 1998, 41, 4360-4364
38. Hermone, A. R.; Burnett, J. C.; Nuss, J. E.; Tressler, L. E.; Nguyen, T. L.; Šolaja, B. A.; Vennerstrom, J. L.; Schmidt, J. J.; Wipf, P.; Bavari, S.; Gussio, R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype a inhibitors in a three-zone pharmacophore ChemMedChem 2008, 3, 1905-1912
39. Chong, C. R.; Sullivan, D. J., Jr. New uses for old drugs Nature 2007, 448, 645-646
40. Sundar, S.; Jha, T. K.; Thakur, C. P.; Engel, J.; Sindermann, H.; Fischer, C.; Junge, K.; Bryceson, A.; Berman, J. Oral miltefosine for Indian visceral leishmaniasis N. Engl. J. Med. 2002, 347, 1739-1746
41. Shen, Y.; Zhukovskaya, N L.; Zimmer, M. I.; Soelaiman, S.; Bergson, P.; Wang, C. R.; Gibbs, C. S.; Tang, W. J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 3242-3247
42. Takano, Y.; Shiga, F.; Asano, J.; Ando, N.; Uchiki, H.; Fukuchi, K.; Anraku, T. Design, synthesis, and AMPA receptor antagonistic activity of a novel 6-nitro-3-oxoquinoxaline-2-carboxylic acid with a substituted phenyl group at the 7 position Bioorg. Med. Chem. 2005, 13, 5841-5863
43. Madrid, P. B.; Wilson, N. T.; DeRisi, J. L.; Kiplin Guy, R. Parallel synthesis and antimalarial screening of a 4-aminoquinoline library J. Comb. Chem. 2004, 6, 437-442
44. Madrid, P. B.; Liou, A. P.; DeRisi, J. L.; Kiplin Guy, R. Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum J. Med. Chem. 2006, 49, 4535-4543
45. Ray, S.; Madrid, P. B.; Catz, P.; LeValley, S. E.; Furniss, M. J.; Rausch, L. L.; Kiplin Guy, R.; DeRisi, J. L.; Iyer, L. V.; Green, C. E.; Mirsalis, J. C. Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models J. Med. Chem. 2010, 53, 3685-3695
46. 50 (CQ) = 1.21). For details see ref: Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D.; Todorović, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; Nuss, J. E.; Wanner, L.; Panchal, R. G.; Šolaja, B. A.; Bavari, S. A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype a light chain, P. falciparum malaria, and the ebola filovirus J. Med. Chem. 2011, 54, 1157-1169
47. Johnson, J. D.; Dennull, R. A.; Gerena, L.; Lopez-Sanchez, M.; Roncal, N. E.; Waters, N. C. Assessment and continued validation of the malaria sybr green i-based fluorescence assay for use in malaria drug screening Antimicrob. Agents Chemother. 2007, 51, 1926-1933
48. Plouffe, D.; Brinker, A.; McNamara, C.; Henson, K.; Kato, N.; Kuhen, K.; Nagle, A.; Adrián, F.; Matzen, J. T.; Anderson, P.; Nam, T.; Gray, N. S.; Chatterjee, A.; Janes, J.; Yan, S. F.; Trager, R.; Caldwell, J. S.; Schultz, P. G.; Zhou, Y.; Winzeler, E. A. From the cover: in silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 9059-9064
49. Ferrari, M.; Fornasiero, M. C.; Isetta, A. M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro J. Immunol. Methods 1990, 131, 165-172